Theravance infectious, gastrointestinal, pulmonary news
Theravance said it expects to complete next quarter its separation into two publicly traded companies. One company - Theravance Inc. - will manage all development and commercial responsibilities plus potential royalty revenues for long-acting adrenergic receptor beta 2 agonist (LABA) products partnered with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.). The products, which are in development for asthma and chronic obstructive pulmonary disease (COPD), are Relvar/Breo fluticasone furoate/vilanterol; Anoro Ellipta umeclidinium bromide/vilanterol; and vilanterol. Fluticasone furoate/vilanterol is approved in the U.S. as Breo Ellipta and in the EU as Relvar Ellipta. Anoro Ellipta is approved in the U.S. and is under review in Europe. ...